Fruquintinib Combined with Sintilimab As Second-line Therapy for Gastric or Gastro-esophageal Junction Adenocarcinoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Peking University Cancer Hospital & Institute
Peking University
Institut Paoli-Calmettes
University Hospital, Essen
Asan Medical Center
Centre Hospitalier Universitaire Vaudois
Guangxi Medical University
P. Herzen Moscow Oncology Research Institute
Beijing Friendship Hospital
Panolos Bioscience
Universitair Ziekenhuis Brussel
Shandong Provincial Hospital
Zhejiang University
University of Maia
Celon Pharma SA
China Medical University, China
Aurigene Discovery Technologies Limited
Henan Cancer Hospital
First People's Hospital of Hangzhou
Regina Elena Cancer Institute
The First Affiliated Hospital of Zhengzhou University
Chinese PLA General Hospital
RenJi Hospital
Hebei Medical University
Fujian Cancer Hospital
Chongqing Precision Biotech Co., Ltd
Kidney Cancer Research Bureau
Zhejiang University
RemeGen Co., Ltd.
RemeGen Co., Ltd.
Royal Marsden NHS Foundation Trust
Changhai Hospital
Assiut University
Zhejiang Cancer Hospital
National Cheng-Kung University Hospital
Icahn School of Medicine at Mount Sinai
Ajou University School of Medicine
National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos
Base Therapeutics (Shanghai) Co., Ltd.
Massachusetts General Hospital
Hebei Medical University
Minneamrita Therapeutics LLC
Imperial College London
University of California, Davis
Shanghai East Hospital
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Kyungpook National University Hospital
Jinling Hospital, China
Zhongnan Hospital